Pembrolizumab in treatment of advanced prostate cancer

We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …

Xofigo (radium-223 acetate) should NOT be used in combination with abiraterone acetate

In December last year we noted an announcement by Bayer that the company was unblinding data from an ongoing clinical trial because of a potential safety issue when radium-223 (Xofigo) was given in combination with abiraterone acetate + prednisone. … READ MORE …

Patient choice and the effectiveness and safety of HIFU

An interesting article has just been published in the Journal of Urology which helps to provide information (and context) about the quality of data supporting the use of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer. … READ MORE …

Upcoming clinical trial of PSMA-linked lutetium-177 in recurrent mCRPC

According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Enzalutamide treatment and risk for seizures

The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: … READ MORE …

Radium-223 + abiraterone acetate: a potential safety issue

Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …

At ASCO this year … “one that got away”

An abstract that we missed at the ASCO meeting this year came to our attention when we read this article by Dr. Jeffrey Kirshner: “Ten practice changes I will make after attending ASCO 2017“. … READ MORE …